Ipsen SA (EURONEXT:IPN) is expanding its oncology and rare-disease pipeline with buys of Kartos (navtemadlin) and Memo Therapeutics (potravitug) totaling up to ≈€2.6bn in milestones, while managing share buybacks and an arbitration with Galderma amid investor concerns over rising deal costs in China.
Previous Week Recap
- Ipsen To Buy Kartos For $450M: Ipsen (IPN) will buy Kartos for $450M upfront plus up to $1.3B milestones to add navtemadlin (oral MDM2 inhibitor) in Phase III for myelofibrosis; close aimed by Q3 2026; top-line data 2027.
- Ipsen To Buy Memo Therapeutics: Ipsen to buy Memo Therapeutics for €200M upfront, up to >€700M with milestones. Deal transfers potravitug (Phase II anti‑BK polyomavirus; FDA fast‑track, EU orphan). Close expected Q3 2026.
- Ipsen Weekly Buyback Activity: Ipsen SA (IPN) disclosed weekly buyback activity for Week 26, 2026, detailing daily and market-level executions of its share repurchase program relevant to traders.
- Ipsen Arbitration With Galderma: Ipsen SA (IPN) in arbitration with Galderma over development and commercialization rights to botulinum toxin Relfydess (relabotulinumtoxinA); dispute handled via arbitration, not public court.
- Ipsen Shares Dip On China Licensing Costs: Ipsen SA (IPN) shares fell ~1.6% after CBO Philippe Lopes-Fernandes said bigger pharma in China has boosted licensing competition and pushed up deal costs, eroding China’s prior cost edge.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.